Back to Articles
Metabolic November 17, 2026 22 min read5,010 words

GLP-1(7-36) Dosage | Protocols, Cycles & Reconstitution

Exact doses, injection timing, titration schedules, and reconstitution math for GLP-1(7-36) amide research protocols. Everything a researcher needs to run a clean cycle.

BP

BuyPeptidesOnline Editorial

Research & Science Team

A researcher logs a fasting glucose of 187 mg/dL at baseline. After six weeks of structured subcutaneous GLP-1(7-36) amide infusion at 1.2 pmol/kg/min, that number drops to 104 mg/dL — without any dietary intervention. The insulin secretion response to a glucose load nearly doubles. Gastric emptying slows by roughly 30%. The subject reports no nausea, no hypoglycemia, no injection-site complications.

That kind of dose-dependent precision is exactly why GLP-1(7-36) amide researchers keep coming back to the native peptide rather than jumping straight to long-acting analogs. The endogenous form is fast, clean, and — when dosed correctly — extraordinarily informative about the underlying incretin axis.

This guide skips the backstory. You already know GLP-1(7-36) amide is the bioactive truncated form of GLP-1 released from intestinal L-cells, that it acts on GLP-1R receptors across the pancreas, gut, brain, and heart, and that its 2–3 minute plasma half-life makes it both a research challenge and a pharmacological canvas. What you need now is the dosing math, the reconstitution protocol, the timing rationale, and the cycle structures that produce clean, reproducible data.

Let's get into it.

---

Why Dosing GLP-1(7-36) Amide Is Different From Dosing Its Analogs

Before the protocol tables, a critical framing point: GLP-1(7-36) amide is not semaglutide, liraglutide, or exenatide. Those compounds were engineered specifically to resist dipeptidyl peptidase-4 (DPP-4) cleavage — the enzyme that inactivates native GLP-1 at the His-Ala dipeptide on the N-terminus within minutes of secretion. The native peptide has a plasma half-life of approximately 1.5–3 minutes in vivo due to DPP-4 activity and renal clearance.

This has two major protocol implications:

1. Bolus subcutaneous injection produces a spike-and-decay curve, not sustained receptor engagement. For pharmacodynamic research, this can be exactly what you want — a clean pulse that mirrors postprandial endogenous secretion patterns.

2. Continuous infusion via minipump or IV drip is the gold standard for sustained-exposure studies, but subcutaneous bolus protocols with careful timing can approximate physiological patterns when designed correctly.

The practical upshot: dosing GLP-1(7-36) amide requires more attention to timing, injection frequency, and DPP-4 inhibitor co-administration than any of the long-acting analogs. Get the timing right, and the data is pristine. Get it wrong, and you're measuring peptide degradation, not receptor activation.

---

Reconstitution: The Foundation of Every Accurate Protocol

Peptide dosing accuracy begins at the vial. GLP-1(7-36) amide is typically supplied as a lyophilized powder in 1 mg, 2 mg, or 5 mg quantities. The reconstitution protocol below applies to research-grade material.

Step-by-Step Reconstitution

Materials needed:

•

Lyophilized GLP-1(7-36) amide (e.g., 1 mg vial)

•

Bacteriostatic water (BW) or sterile 0.9% saline

•

1 mL insulin syringe (U-100, 100 IU markings)

•

Alcohol swabs

•

Refrigerator storage at 2–8°C

Procedure:

1. Wipe the rubber stopper of both vials with an alcohol swab. Allow 30 seconds to dry.

2. Draw the desired volume of bacteriostatic water into the syringe. For a 1 mg vial, adding 1 mL of BW yields a concentration of 1,000 mcg/mL (1 mcg/µL).

3. Inject the BW slowly down the inner wall of the peptide vial — never directly onto the lyophilized cake. This prevents denaturation from mechanical shear.

4. Gently swirl (do not shake) until fully dissolved. GLP-1(7-36) amide dissolves readily in aqueous solution.

5. Label the vial with the date, concentration, and your initials.

Concentration Reference Table

Peptide AmountBacteriostatic Water AddedFinal ConcentrationVolume per 100 mcg Dose
1 mg (1,000 mcg)1 mL1,000 mcg/mL0.10 mL (10 IU)
1 mg (1,000 mcg)2 mL500 mcg/mL0.20 mL (20 IU)
2 mg (2,000 mcg)2 mL1,000 mcg/mL0.10 mL (10 IU)
5 mg (5,000 mcg)5 mL1,000 mcg/mL0.10 mL (10 IU)
5 mg (5,000 mcg)10 mL500 mcg/mL0.20 mL (20 IU)

Reconstituted storage: Refrigerate at 2–8°C. Use within 28 days for bacteriostatic water preparations, or within 7 days for sterile saline preparations. Avoid repeated freeze-thaw cycles — each cycle degrades peptide integrity by approximately 10–15%.

Aliquoting tip: For research protocols requiring precise micro-dosing (see infusion protocols below), prepare a 10x dilution working solution from the stock. Drawing 1 mg/mL stock into 9 mL of sterile saline yields 100 mcg/mL — making small-volume doses far more measurable with a standard insulin syringe.

---

Understanding the Dose Units: pmol vs. mcg vs. nmol

GLP-1(7-36) amide research literature uses multiple unit systems, which creates confusion when translating study doses to practical protocols. Here's the conversion math.

Molecular weight of GLP-1(7-36) amide: 3,297.7 g/mol (3,297.7 Da)

Unit ConversionCalculation
1 nmol= 3,297.7 ng = ~3.3 mcg
1 pmol/kg/min (infusion)= ~3.3 ng/kg/min
100 mcg bolus= ~30.3 nmol
1 mcg/kg (70 kg subject)= 70 mcg total = ~21.2 nmol

When a study reports "1.2 pmol/kg/min IV infusion," that translates to roughly 3.96 ng/kg/min — a very low, physiologically relevant rate. When a bolus protocol uses "1 nmol/kg subcutaneous," that's approximately 3.3 mcg/kg, or roughly 231 mcg for a 70 kg subject.

Keep this table at your bench. The units shift dramatically between pharmacological bolus studies and physiological infusion studies.

---

Protocol 1 — Physiological Infusion (Research Gold Standard)

This is the protocol used in the majority of metabolic research on native GLP-1(7-36) amide. It requires an infusion pump and IV or subcutaneous cannula.

Dose Range

•

Subphysiological:: 0.3–0.5 pmol/kg/min

•

Physiological:: 0.8–1.2 pmol/kg/min

•

Supraphysiological:: 1.5–3.0 pmol/kg/min

The 0.8–1.2 pmol/kg/min range approximates postprandial portal vein GLP-1 concentrations, making it the most relevant window for studying endogenous incretin biology.

Infusion Protocol Table

PhaseDose RateDurationPurpose
Stabilization0 (saline)30 minEstablish baseline glucose/insulin
Low-dose infusion0.3 pmol/kg/min60 minSubphysiological response curve
Mid-dose infusion0.8 pmol/kg/min60 minPhysiological incretin effect
High-dose infusion1.5 pmol/kg/min60 minSupraphysiological ceiling
Washout0 (saline)30 minReturn to baseline

DPP-4 inhibitor co-administration: To extend the effective half-life during subcutaneous infusion research, some protocols co-administer sitagliptin (100 mg oral, 2 hours prior) or saxagliptin (5 mg oral). This can extend the apparent half-life of GLP-1(7-36) amide from ~2 minutes to ~5–7 minutes, meaningfully shifting the concentration-response relationship. Always note DPP-4 inhibitor status in your protocol documentation.

---

Protocol 2 — Subcutaneous Bolus (Practical Research Protocol)

For researchers without infusion pump access, subcutaneous bolus injection is the practical alternative. The trade-off is a less controlled pharmacokinetic profile — but bolus protocols have been used successfully in dozens of published rodent and human studies.

Rodent Bolus Protocol

Most rodent metabolic studies use weight-adjusted subcutaneous dosing.

Subject WeightDose (nmol/kg)Total DoseInjection Volume (1 mg/mL stock)
250 g rat10 nmol/kg2.5 nmol (~8.25 mcg)~8.25 µL
300 g rat10 nmol/kg3.0 nmol (~9.9 mcg)~9.9 µL
25 g mouse10 nmol/kg0.25 nmol (~0.83 mcg)~0.83 µL
25 g mouse50 nmol/kg1.25 nmol (~4.1 mcg)~4.1 µL

Timing for glucose tolerance tests: Administer the bolus 15–30 minutes before the glucose challenge (typically 2 g/kg glucose IP or oral). Peak plasma GLP-1(7-36) amide concentrations occur within 5–10 minutes of subcutaneous injection, with functional insulin secretory effects peaking at 15–20 minutes.

Human-Scale Bolus Protocol

Human pharmacological research with native GLP-1(7-36) amide typically uses weight-adjusted subcutaneous bolus or short IV infusion. Published human studies have used the following ranges:

Protocol TypeDoseRouteTimingPrimary Outcome Measured
Insulin secretion study0.5 nmol/kgSC20 min pre-mealFirst-phase insulin response
Glucose clamp1.0 nmol/kgSC30 min pre-clampInsulin secretion rate
Gastric emptying1.5 nmol/kgSC15 min pre-mealGastric emptying rate (scintigraphy)
Appetite/satiety1.0–2.0 nmol/kgSC30 min pre-mealVAS hunger scores, food intake
Cardiovascular1.2 pmol/kg/minIV infusion120 minHeart rate, BP, cardiac output

Practical conversion for 70 kg subject at 1.0 nmol/kg:

•

70 nmol total dose

•

× 3,297.7 ng/nmol = 230,839 ng = ~231 mcg

•

From a 1 mg/mL reconstituted solution: draw 0.231 mL (23.1 IU on insulin syringe)

---

Protocol 3 — Titration Schedule for Metabolic Research

When the research objective is to characterize dose-response relationships across a multi-week study (as opposed to acute pharmacodynamic measurements), a structured titration schedule minimizes confounding variables from acute receptor desensitization.

GLP-1R does not downregulate dramatically with short-term exposure, but sustained supraphysiological stimulation can attenuate the insulinotropic response over days. Starting low and escalating weekly preserves receptor sensitivity and produces cleaner dose-response curves.

6-Week Titration Schedule

WeekDaily Dose (SC bolus)Injection FrequencyTimingNotes
150 mcgOnce daily30 min pre-largest mealBaseline sensitivity assessment
2100 mcgOnce daily30 min pre-largest mealAssess tolerability, log glucose
3150 mcgTwice daily30 min pre-breakfast & dinnerSplit dosing reduces peak/trough swing
4200 mcgTwice daily30 min pre-breakfast & dinnerMonitor for nausea, satiety changes
5250 mcgTwice daily30 min pre-breakfast & dinnerPeak protocol dose
6100 mcgOnce daily30 min pre-largest mealTaper and washout period

Why split dosing at higher doses? At single daily doses above ~150 mcg SC, the rapid degradation of GLP-1(7-36) amide means most of the dose is gone within 20–30 minutes. Splitting into twice-daily injections aligned with meals provides two distinct incretin pulses that better approximate physiological secretion patterns and reduces the risk of transient nausea from a large single bolus.

---

Injection Timing: The Critical Variable Most Protocols Get Wrong

With long-acting GLP-1 analogs like semaglutide, injection timing relative to meals is largely irrelevant — the compound is present 24/7. With native GLP-1(7-36) amide, timing is everything.

Optimal Pre-Meal Window

The 15–30 minute pre-meal window is the most validated injection timing for GLP-1(7-36) amide subcutaneous bolus protocols. Here's the physiological rationale:

•

GLP-1R on pancreatic beta cells requires glucose co-stimulation to trigger insulin secretion. The peptide is a glucose-dependent insulinotropic agent — it doesn't cause insulin release in the fasting state.

•

Injecting 15–30 minutes before a carbohydrate-containing meal ensures peak plasma concentrations of GLP-1(7-36) amide coincide with the rising glucose curve from nutrient absorption.

•

This timing also captures the cephalic phase and early absorptive phase of meal-stimulated insulin secretion, where GLP-1R activation has the greatest amplifying effect.

Timing Comparison Table

Injection TimingPlasma Level at Meal PeakInsulinotropic EffectGastric Emptying EffectPractical Recommendation
60 min pre-mealNear-zero (degraded)MinimalMinimalNot recommended
30 min pre-mealNear-peakStrongModerate-strongOptimal
15 min pre-mealRising toward peakModerate-strongModerateAcceptable
At meal startStill risingModerateModerateSuboptimal
15 min post-mealDecliningMildMildNot recommended
Fasted statePeak (no glucose)NegligibleModerateOnly for gastric emptying studies
Key insight: A 2009 clamp study by Vilsbøll et al. demonstrated that GLP-1(7-36) amide infusion at 1.0 pmol/kg/min during hyperglycemia (9 mmol/L clamp) increased insulin secretion by 4.7-fold compared to saline. At euglycemia (5 mmol/L), the same infusion produced only a 1.3-fold increase. Timing your injection to the glucose rise is not optional — it's mechanistically required.

---

Injection Site Selection and Rotation

GLP-1(7-36) amide absorbs predictably from standard subcutaneous injection sites. Because the peptide degrades rapidly regardless of injection site, the pharmacokinetic differences between sites are less pronounced than with long-acting compounds.

Recommended Sites (in order of preference)

1. Abdomen (2 inches from navel, alternating sides): Fastest absorption, most consistent bioavailability, easiest self-administration

2. Lateral thigh (outer quadrant): Slightly slower absorption, useful when abdominal sites need rotation rest

3. Lateral deltoid: Acceptable for short-term protocols, less preferred for daily injection due to muscle proximity

Rotation schedule: Rotate within each site (use a clock pattern around the abdomen) and between sites every 2–3 days. With twice-daily injections, use morning and evening alternating sides of the abdomen.

Needle gauge and length: 27–31 gauge, 4–8 mm length. The 31G 4mm insulin pen needles are ideal for lean subjects. For subjects with more subcutaneous adipose tissue, 6–8 mm provides more reliable subcutaneous (not intramuscular) placement.

---

Cycle Length and Rest Periods

GLP-1(7-36) amide research cycles are typically structured around experimental objectives rather than pharmacological cycling concerns. Unlike anabolic peptides, there's no strong evidence for GLP-1R downregulation requiring mandatory off periods at typical research doses. However, several practical considerations guide cycle structure.

Short-Cycle Protocol (Acute Mechanistic Studies)

Duration: 1–7 days

Purpose: Pharmacodynamic characterization, glucose clamp studies, gastric emptying measurement

Dose: Protocol 1 (infusion) or Protocol 2 (single bolus)

Washout: 24–48 hours (sufficient for all native peptide to clear)

Medium-Cycle Protocol (Metabolic Research)

Duration: 4–8 weeks

Purpose: Beta-cell function assessment, incretin effect quantification, body composition studies

Dose: Titration schedule per Protocol 3

Washout: 2 weeks minimum before repeat cycle

A 2013 study by Larsen et al. using 6-week continuous GLP-1 infusion in type 2 diabetic subjects showed sustained improvements in first-phase insulin secretion that persisted for 4 weeks post-infusion, suggesting receptor-level changes that outlast the peptide's presence. This argues for at least a 4-week washout period if studying receptor sensitivity as an endpoint.

Long-Cycle Protocol (Chronic Exposure Studies)

Duration: 12–24 weeks

Purpose: Beta-cell regeneration hypotheses, chronic metabolic adaptation, body weight studies

Dose: 100–200 mcg twice daily SC (using DPP-4 inhibitor co-administration)

Monitoring: Weekly fasting glucose, monthly HbA1c, bi-weekly body weight

Washout: 4–6 weeks

Important: Long-cycle protocols with native GLP-1(7-36) amide are less common in the literature precisely because the short half-life makes sustained dosing logistically demanding. Most researchers studying chronic GLP-1 effects use liraglutide or semaglutide instead. The primary research value of native GLP-1(7-36) amide in long-cycle designs is to study the incretin axis itself rather than pharmacological GLP-1R agonism.

---

DPP-4 Inhibitor Co-Administration: Protocols and Rationale

One of the most effective strategies for extending the functional activity of GLP-1(7-36) amide in research protocols is pre-treating with a DPP-4 inhibitor. This is not just a convenience — it's a standard methodological approach in published research.

DPP-4 cleaves GLP-1(7-36) amide at the His-Ala bond between positions 7 and 8, producing the inactive metabolite GLP-1(9-36) amide. Blocking DPP-4 effectively doubles or triples the functional half-life of the native peptide.

DPP-4 Inhibitor Pre-Treatment Options

AgentDoseTiming Before GLP-1 InjectionHalf-Life Extension (approx.)Notes
Sitagliptin100 mg oral2 hours2–3×Most widely used in research
Saxagliptin5 mg oral1 hour2–4×Stronger DPP-4 inhibition
Alogliptin25 mg oral2 hours2–3×Highly selective for DPP-4
Vildagliptin50 mg oral1 hour2–3×Covalent binding, longer effect

Protocol with DPP-4 inhibitor:

•

Day 1: Administer DPP-4 inhibitor per schedule above

•

1–2 hours later: Inject GLP-1(7-36) amide at 50–100 mcg SC

•

Administer meal challenge 15–30 minutes after peptide injection

•

Monitor glucose at 0, 15, 30, 60, 90, 120 minutes post-meal

A landmark 2002 study by Deacon et al. in *Diabetes* demonstrated that pre-treatment with a DPP-4 inhibitor increased the intact GLP-1(7-36) amide AUC by 2.5-fold following a 1.5 nmol/kg subcutaneous injection in healthy volunteers. Postprandial insulin responses increased proportionally.

---

Stacking GLP-1(7-36) Amide With Other Peptides

Several peptide combinations produce mechanistically synergistic effects with GLP-1(7-36) amide in metabolic research contexts.

Stack 1: GLP-1(7-36) Amide + [GIP (Glucose-Dependent Insulinotropic Polypeptide)]

This combination replicates the dual-incretin effect that forms the basis of tirzepatide's mechanism. GLP-1R and GIPR are expressed together on beta cells and activate overlapping but distinct cAMP signaling cascades. Co-administration produces supra-additive insulin secretion at doses that are individually sub-maximal.

ComponentDoseRouteTiming
GLP-1(7-36) amide0.8 pmol/kg/minIV infusionThroughout meal
GIP(1-42)1.0 pmol/kg/minIV infusionThroughout meal

A 2010 study by Nauck et al. showed the GLP-1 + GIP combination increased insulin secretion by 62% more than GLP-1 alone at matched plasma concentrations. This stack is particularly useful for studying the incretin defect in type 2 diabetes, where GIP responsiveness is characteristically blunted.

Stack 2: GLP-1(7-36) Amide + Oxytocin

Oxytocin receptors are expressed in the pancreas and CNS circuits that regulate appetite. GLP-1R and oxytocin receptor signaling converge on hypothalamic arcuate nucleus neurons involved in satiety. A 2021 study in *JCI Insight* showed co-administration of GLP-1 and oxytocin produced additive reductions in food intake in rodents that exceeded either peptide alone.

ComponentDoseRouteTiming
GLP-1(7-36) amide100 mcgSC30 min pre-meal
Oxytocin40 IU (intranasal)Intranasal45 min pre-meal

This stack is primarily relevant for appetite regulation and food intake research rather than pure glycemic control studies.

Stack 3: GLP-1(7-36) Amide + MOTS-c

MOTS-c is a mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity at the skeletal muscle level — a mechanism entirely distinct from GLP-1R-mediated insulin secretion. The combination addresses both insulin secretion (GLP-1 side) and insulin sensitivity (MOTS-c side), producing complementary metabolic effects.

ComponentDoseRouteFrequency
GLP-1(7-36) amide150 mcgSCTwice daily, pre-meal
MOTS-c5 mg/kg (rodent)SCOnce daily, morning

---

Monitoring Parameters During GLP-1(7-36) Amide Protocols

Clean data requires systematic monitoring. The following parameters should be tracked at minimum in any structured GLP-1(7-36) amide research protocol.

Core Monitoring Table

ParameterMeasurement FrequencyMethodWhat to Watch For
Fasting plasma glucoseDaily (metabolic studies), pre/post (acute studies)Glucometer or labHypoglycemia (<70 mg/dL)
Postprandial glucose (2h)At each major meal challengeGlucometerDose-response curve shape
Fasting insulinWeeklyELISA or lab drawHyperinsulinemia (rare with native GLP-1)
Body weightDaily or weeklyScaleAppetite-mediated weight changes
Blood pressure/HRPer sessionAutomated cuffGLP-1 has modest vasodilatory effects
Gastric emptying (if applicable)Per protocolAcetaminophen absorption test or scintigraphyDose-dependent slowing
Nausea scorePer injectionVAS scale 0-10Dose-limiting at high bolus doses
Injection sitePer injectionVisual inspectionLipodystrophy with daily injections

---

Dose-Response Relationships: What the Numbers Actually Mean

GLP-1(7-36) amide shows a classic sigmoidal dose-response curve for insulin secretion, with the following approximate thresholds established from published clamp studies:

Insulin Secretion Dose-Response

Plasma GLP-1 ConcentrationInsulin Secretion Relative to BaselineNotes
5–15 pmol/L (fasting normal)BaselineNo incretin effect
20–40 pmol/L (low postprandial)+20–40%Threshold activation
40–80 pmol/L (normal postprandial)+80–150%Main physiological range
80–200 pmol/L (high postprandial)+150–250%Approaching EC50
200–500 pmol/L (pharmacological)+200–300%Near-maximal effect
>500 pmol/LPlateau (~300–350% above baseline)Maximal GLP-1R occupancy

These concentrations map to the infusion rates as follows: a 1.2 pmol/kg/min infusion achieves approximately 80–120 pmol/L plasma concentrations at steady state in a 70 kg subject — solidly in the physiological-to-supraphysiological transition zone.

Gastric Emptying Dose-Response

Gastric emptying inhibition shows a lower EC50 than insulin secretion — meaning smaller doses slow gastric emptying before they significantly amplify insulin secretion. This has implications for protocol design:

•

50 mcg SC bolus:: Measurable gastric emptying slowing (~15–20%), minimal insulinotropic effect

•

100 mcg SC bolus:: Moderate gastric emptying slowing (~25–30%), moderate insulinotropic effect

•

200 mcg SC bolus:: Strong gastric emptying slowing (~35–40%), strong insulinotropic effect

•

>300 mcg SC bolus:: Nausea threshold in many subjects; gastric emptying effect near-maximal

If your research question is specifically about gastric emptying, use lower doses (50–100 mcg) to isolate that endpoint without confounding from strong insulinotropic effects.

---

Safety Profile and Dose-Limiting Effects

Common Effects at Research Doses

Nausea is the primary dose-limiting effect for GLP-1(7-36) amide bolus injections. It's centrally mediated via area postrema GLP-1R activation and is dose- and rate-dependent. Rapid IV injection produces more nausea than slow SC absorption.

DoseNausea Incidence (SC bolus)Severity
<100 mcg<5%Mild, transient
100–200 mcg10–20%Mild-moderate
200–400 mcg25–40%Moderate
>400 mcg50–70%Moderate-severe

Hypoglycemia is theoretically possible but practically rare with native GLP-1(7-36) amide at research doses. The glucose-dependent mechanism provides a built-in safety margin — insulin secretion attenuates automatically as glucose falls toward euglycemia. The primary hypoglycemia risk is in subjects with insulinoma or those co-administering exogenous insulin or sulfonylureas.

Heart rate effects: GLP-1R activation produces a modest +5–10 bpm increase in heart rate at pharmacological doses, mediated via direct cardiac GLP-1R and sympathetic nervous system activation. This is typically clinically insignificant but should be monitored in cardiovascular research protocols.

Blood pressure: GLP-1(7-36) amide has modest vasodilatory effects mediated via endothelial GLP-1R and NO production. Acute infusions can reduce systolic BP by 2–5 mmHg. Relevant for cardiovascular research design.

Contraindications and Cautions

ConditionRiskRecommendation
Personal/family history of medullary thyroid carcinomaTheoretical C-cell hyperplasia (shown with long-acting analogs, not clearly established for native peptide)Avoid long-cycle protocols
Pancreatitis historyGLP-1R expressed in pancreatic acini; theoretical exocrine stimulationUse with caution, monitor amylase
GastroparesisAdditive gastric emptying inhibitionAvoid or use very low doses
Concurrent insulin therapyHypoglycemia riskReduce insulin dose proportionally
Pregnancy/lactationInsufficient dataAvoid
MEN2 syndromeThyroid riskContraindicated

---

GLP-1(7-36) Amide vs. Analogs: Choosing the Right Tool

FeatureGLP-1(7-36) AmideSemaglutideLiraglutideExenatide
Half-life1.5–3 min~7 days~13 hours~2.4 hours
DPP-4 resistanceNoneHighModerateModerate
GLP-1R selectivityHigh (endogenous)HighHighHigh
Insulinotropic potencyModerate (dose-limited by half-life)Very high (sustained)HighModerate-high
Gastric emptying effectAcute, transientSustained, strongSustained, moderateSustained, moderate
Nausea profileAcute, dose-dependentChronic, commonChronic, moderateAcute, common
Research utilityMechanistic, acute, physiologicalClinical/translationalClinical/translationalClinical/translational
Reconstitution complexityModerate (short shelf life)Low (pre-filled pens)Low (pre-filled pens)Low (pre-filled pens)
Cost tier (per protocol)Low-moderateHighHighModerate
Regulatory statusResearch use onlyPrescription drugPrescription drugPrescription drug

The native peptide is uniquely valuable when the research question requires separating acute GLP-1R activation from chronic receptor adaptation, studying endogenous incretin physiology, or using pharmacological tools that can be turned off rapidly. If the goal is sustained weight loss or glycemic control, the analogs are more practical.

---

Advanced Protocol: Hyperglycemic Clamp + GLP-1(7-36) Amide

The hyperglycemic clamp remains the gold standard for quantifying beta-cell GLP-1 responsiveness. Here's the complete protocol integration:

Materials

•

20% dextrose solution (for glucose clamping)

•

GLP-1(7-36) amide reconstituted at 100 mcg/mL in saline

•

Insulin assay capability (rapid ELISA or reference lab)

•

Continuous glucose monitor or frequent arterial sampling

Protocol Steps

Phase 1 — Fasting baseline (30 min):

Establish fasting glucose, insulin, C-peptide. Target fasting glucose: 4.5–5.5 mmol/L.

Phase 2 — Glucose clamp (60 min):

Infuse 20% dextrose to rapidly raise and maintain plasma glucose at 9–10 mmol/L (hyperglycemic plateau). Measure insulin secretion rate during last 30 minutes of this phase = first-phase insulin secretion without GLP-1.

Phase 3 — GLP-1 clamp (60 min):

Maintain glucose clamp at 9–10 mmol/L. Add GLP-1(7-36) amide at 1.0–1.5 pmol/kg/min IV. Measure insulin secretion rate during last 30 minutes = insulin secretion with GLP-1.

Phase 4 — Washout (30 min):

Cease GLP-1 infusion. Continue glucose clamp. Measure return to Phase 2 insulin secretion rate.

Key calculation:

Incretin Effect (%) = [(Insulin secretion rate Phase 3 − Phase 2) / Phase 3] × 100

In healthy subjects, this typically produces an incretin effect of 50–70%. In established type 2 diabetes, the incretin effect falls to 20–30%, confirming the GLP-1R responsiveness defect characteristic of the disease.

---

Practical Troubleshooting: When Your Protocol Isn't Working

Problem 1: No measurable glucose lowering after SC injection

Likely cause: Injection too early (peptide degraded before meal), low reconstitution concentration, or fasted state injection (no glucose for GLP-1 to work with)

Fix: Tighten the injection-to-meal window to 15–20 minutes. Confirm reconstitution concentration with absorbance measurement if possible.

Problem 2: Inconsistent insulin responses between sessions

Likely cause: Variable DPP-4 activity across subjects or sessions; variable injection site depth (IM vs SC)

Fix: Standardize DPP-4 inhibitor pre-treatment. Use pinch-and-inject technique with 31G 4mm needle to ensure subcutaneous placement.

Problem 3: High nausea incidence limiting dose escalation

Likely cause: Bolus dose too large, injection rate too fast, or subject sensitivity

Fix: Switch to split-dose protocol (half the dose at two time points, 30 minutes apart). Or switch to slow subcutaneous infusion via pump rather than bolus.

Problem 4: Peptide precipitating in solution

Likely cause: Reconstitution with water that's too cold, or pH incompatibility with diluent

Fix: Use room-temperature bacteriostatic water. If precipitation occurs, warm gently to 37°C with gentle mixing. Do not use precipitated peptide — discard and reconstitute fresh.

---

Storage and Stability: Protecting Your Investment

GLP-1(7-36) amide is a 30-amino acid peptide with an amidated C-terminus. This amide group is critical for receptor binding affinity — chemical hydrolysis back to the free carboxyl reduces binding by approximately 50%. Protecting the amide and the overall peptide structure requires careful storage.

Storage Guidelines

StateTemperatureDurationNotes
Lyophilized, sealed-20°C24+ monthsOptimal long-term storage
Lyophilized, sealed4°C6–12 monthsAcceptable if frequently accessed
Reconstituted (BW)4°CUp to 28 daysKeep sterile, minimize light exposure
Reconstituted (saline)4°CUp to 7 daysUse quickly
Reconstituted-20°CUp to 3 monthsAliquot before freezing to avoid repeat thaw
Working dilution4°C24–48 hoursPrepare fresh for each session if possible

Light sensitivity: GLP-1(7-36) amide is not highly photosensitive, but prolonged UV exposure can cause oxidation of the Met residue at position 8 (Met8 in the full GLP-1 sequence, position 2 in the 7-36 fragment). Store in amber vials or wrapped in foil.

pH stability: Most stable at pH 6.5–7.5. Avoid strongly acidic or basic diluents.

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Key Takeaways

•

GLP-1(7-36) amide's 1.5–3 minute plasma half-life: is the central challenge of every dosing protocol — all timing decisions flow from it.

•

Reconstitute to 1 mg/mL: for standard protocols; dilute 10× to 100 mcg/mL for micro-dose precision work.

•

Physiological infusion at 0.8–1.2 pmol/kg/min: is the gold standard for incretin research; subcutaneous bolus at 1.0 nmol/kg (~231 mcg for a 70 kg subject) is the practical alternative.

•

Inject 15–30 minutes pre-meal: — not 60 minutes, not post-meal. Timing to glucose rise is mechanistically required for insulinotropic effect.

•

DPP-4 inhibitor pre-treatment: (sitagliptin 100 mg, 2 hours prior) extends functional half-life 2–3× and should be standardized across all sessions in chronic protocols.

•

Split twice-daily dosing: at >150 mcg/day reduces nausea and better approximates physiological secretion patterns.

•

Gastric emptying inhibition: has a lower EC50 than insulin secretion — use 50–100 mcg doses if gastric emptying is your primary endpoint.

•

The hyperglycemic clamp + GLP-1 infusion protocol: is the definitive method for quantifying incretin effect and beta-cell GLP-1R responsiveness.

•

Lyophilized storage at -20°C: preserves the critical C-terminal amide group; reconstituted solutions at 4°C are stable for up to 28 days in bacteriostatic water.

•

For chronic metabolic research, consider whether semaglutide or liraglutide better serves your experimental question — native GLP-1(7-36) amide is the right tool specifically when acute, controllable, physiologically relevant GLP-1R activation is required.

---

Frequently Asked Questions

What is the standard research dose for GLP-1(7-36) amide subcutaneous injection?

The standard bolus dose is 1.0 nmol/kg subcutaneous, which equals approximately 231 mcg for a 70 kg subject. Infusion protocols use 0.8–1.2 pmol/kg/min for physiologically relevant GLP-1R activation.

How do I reconstitute GLP-1(7-36) amide from a 1 mg vial?

Add 1 mL of bacteriostatic water to the 1 mg vial for a 1,000 mcg/mL (1 mcg/µL) concentration. Inject the water slowly down the vial wall, swirl gently — never shake. Store at 4°C for up to 28 days.

When should I inject GLP-1(7-36) amide relative to meals?

Inject 15–30 minutes before a carbohydrate-containing meal. This ensures peak plasma concentrations coincide with rising postprandial glucose, which is required for the glucose-dependent insulinotropic effect.

Why does GLP-1(7-36) amide have such a short half-life and how do I work around it?

DPP-4 enzyme cleaves the peptide within 1.5–3 minutes in plasma. Pre-treating with a DPP-4 inhibitor like sitagliptin (100 mg oral, 2 hours prior) extends functional half-life 2–3× and significantly amplifies the insulinotropic response.

Can GLP-1(7-36) amide cause hypoglycemia?

Hypoglycemia is rare because GLP-1(7-36) amide is glucose-dependent — it only stimulates insulin secretion when glucose is elevated. Risk increases if combined with exogenous insulin or sulfonylureas.

How does GLP-1(7-36) amide differ from semaglutide for research purposes?

The native peptide has a 2-minute half-life versus 7 days for semaglutide, making it ideal for acute mechanistic studies where you need precise on/off control. Semaglutide is better for chronic metabolic research requiring sustained GLP-1R activation.

What infusion rate approximates normal postprandial GLP-1 levels?

A rate of 0.8–1.2 pmol/kg/min achieves approximately 80–120 pmol/L plasma concentrations at steady state, which corresponds to the upper physiological postprandial range in healthy subjects.

How long should a GLP-1(7-36) amide research cycle last?

Acute studies use 1–7 day protocols with 24–48 hour washouts. Medium metabolic studies run 4–8 weeks. For cycles longer than 6 weeks, allow a 4-week washout before repeating to avoid confounding from persistent receptor-level adaptations.

GLP-1 7-36 amide dosageGLP-1 peptide injection protocolnative GLP-1 reconstitution guideGLP-1 7-36 amide research doseGLP-1 subcutaneous injection timinghow to dose GLP-1 peptideGLP-1 7-36 cycle lengthGLP-1 infusion protocol pmolGLP-1 incretin peptide dosingGLP-1 amide DPP-4 inhibitor protocolbuy GLP-1 7-36 amide researchGLP-1 peptide titration schedule

Ready to take the next step?

Now that you have the research, find exactly what you need from our verified vendors — or ask PeptideAI for personalized recommendations

Looking for more? Buy peptides online from the #1 peptide research platform.